Overview

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Phase:
PHASE3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.